company background image
ITRM logo

Iterum Therapeutics NasdaqCM:ITRM Stock Report

Last Price

US$1.54

Market Cap

US$21.4m

7D

-2.5%

1Y

54.7%

Updated

28 Mar, 2024

Data

Company Financials +

Iterum Therapeutics plc

NasdaqCM:ITRM Stock Report

Market Cap: US$21.4m

ITRM Stock Overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.

ITRM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Iterum Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Iterum Therapeutics
Historical stock prices
Current Share PriceUS$1.54
52 Week HighUS$2.50
52 Week LowUS$0.62
Beta2.35
1 Month Change16.67%
3 Month Change-21.83%
1 Year Change54.74%
3 Year Change-92.97%
5 Year Change-98.77%
Change since IPO-99.20%

Recent News & Updates

Recent updates

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Aug 19
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Aug 12

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Jul 11

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

May 06
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Jan 12
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Sep 25
Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Jul 05

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Jun 11
It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

May 20
Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

Feb 04
Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Feb 04
This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Iterum Therapeutics shares slide 13% on raising $10M

Feb 03

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Dec 03

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Nov 30

Iterum Therapeutics EPS beats by $0.45

Nov 16

Shareholder Returns

ITRMUS PharmaceuticalsUS Market
7D-2.5%1.2%0.4%
1Y54.7%25.8%28.8%

Return vs Industry: ITRM exceeded the US Pharmaceuticals industry which returned 25.8% over the past year.

Return vs Market: ITRM exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is ITRM's price volatile compared to industry and market?
ITRM volatility
ITRM Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ITRM's share price has been volatile over the past 3 months.

Volatility Over Time: ITRM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201514Corey Fishmanhttps://www.iterumtx.com

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics plc Fundamentals Summary

How do Iterum Therapeutics's earnings and revenue compare to its market cap?
ITRM fundamental statistics
Market capUS$21.36m
Earnings (TTM)-US$31.10m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ITRM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$31.10m
Earnings-US$31.10m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.31
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio570.9%

How did ITRM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.